Dr Karl Keegan
DIRECTOR OF CORPORATE DEVELOPMENT
pharmacology
Shield Therapeutics
Switzerland
Biography
Dr Karl Keegan joined the Group as Director of Corporate Development in April 2017. Karl brings over 20 years’ experience in the finance sector as a highly ranked sell side analyst and Board Director. Since leaving the financial sector in 2009, Karl has had extensive international financing and corporate development responsibilities with a variety of biotechnology and specialty pharma companies. His previous major role was as Corporate Development Director at Vectura Group plc where he had an integral role in the acquisition of Activaero and associated fundraise in 2014 and the merger with Skyepharma in 2016. Karl has a PhD in pharmacology from the University of Cambridge and a MSc in Finance from London Business School.
Research Interest
Finance , pharmacology
